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We assessed electrophysiological effects of an atypical antipsychotic drug paliperidone in acute atrio-
ventricular block rabbits. Intravenous administration of paliperidone at a clinically relevant dose
(0.06 mg/kg) hardly affected the QT interval or monophasic action potential (MAP) duration, and the
higher doses (0.6 and 6 mg/kg) prolonged the QT interval and MAP duration. Meanwhile, premature
ventricular contractions with R on T phenomenon were observed in 3 out of 6 animals at the middle
dose, and torsades de pointes (TdP) episodes were detected in 2 out of 6 animals at the high dose.
Intravenous administration of its chemically related compound risperidone at a clinically relevant dose
(0.03 mg/kg) hardly affected the electrophysiological parameters, and the higher doses (0.3 and 3 mg/kg)
prolonged the QT interval and MAP duration. Meanwhile, the premature ventricular contractions with R
on T were observed in 2 out of 6 animals at the middle dose, and TdP episodes were detected in 4 out of 6
animals at the high dose. These results suggest that paliperidone showed torsadogenic potential at
supra-therapeutic doses, whose potency can be estimated to be equal or slightly subordinate in com-
parison with that of risperidone.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Paliperidone is a second generation atypical antipsychotic drug
used for the treatment of positive and negative symptoms associ-
ated with schizophrenia, which is also known as a major active
metabolite of risperidone (9-hydroxyrisperidone, Fig. 1) (1,2). For
clinical efﬁcacy, safety and tolerability, extended-release tablets
containing paliperidone have been prescribed once-daily, which
contributes to minimize the 24-h peak-trough variation at steady
state plasma concentration (3,4). On the other hand, prolonged
release suspension of paliperidone palmitate for injection can be
administered once a month after adjustment of the maintenance
dose in adult patients stabilized with paliperidone or risperidonegy and Therapeutics, Faculty
iyama, Funabashi, Chiba 274-
ara).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).(5). In 2014, the Japanese Ministry of Health, Labour and Welfare
issued a blue letter (safety advisory) for the prolonged release
suspension of paliperidone palmitate (6). Finally, a total of 32 fatal
cases had been reported during the Early Post-marketing Phase
Vigilance from its launch on November 2013 up to May 2014 (7).
Although the risk of all-cause mortality in association with the use
of paliperidone was not high in comparison with other in-
vestigations, the most common cause of death was sudden death,
followed by suicide and neuroleptic malignant syndrome (7).
Paliperidone has been reported to cause a modest increase in
the QT interval in clinical practice (3,8), which may be associated
with its inhibitory effects on the human ether-a-go-go-related gene
(hERG) Kþ channels, encoding the pore-forming subunit of rapidly
activating delayed rectiﬁer Kþ current (IKr) (9). Since drug-induced
QT interval prolongation is often associated with the onset of tor-
sades de pointes (TdP) resulting in a life-threatening ventricular
arrhythmia (10,11), further information regarding proarrhythmic
potential of paliperidone is needed to better understand causality
between the drug and its lethal events. It is noteworthy that thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Paliperidone
Risperidone
Fig. 1. Chemical structures of paliperidone and risperidone.
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repolarization may be essentially in accordance with that of its
chemically related compound risperidone (8,12). In this study, we
compared proarrhythmic effects of paliperidone with those of ris-
peridone using acute atrioventricular block rabbits, which is
adopted as a proarrhythmia model (13).2. Materials and methods
All experiments were approved by Toho University Animal Care
and User Committee and performed in accordance with the Guid-
ing Principles for the Care and Use of Laboratory Animals approved
by The Japanese Pharmacological Society. A total of 12 New Zealand
White rabbits (Sankyo Labo Service, Tokyo, Japan) were used in this
study.2.1. Production of atrioventricular block model
Male New ZealandWhite rabbits, weighting approximately 3 kg,
were initially anesthetized with ketamine hydrochloride (35 mg/
kg, i.m.) and xylazine hydrochloride (5 mg/kg, i.m.). After tracheal
intubation,1.5% isoﬂurane vaporizedwith 100% oxygenwas inhaled
with a ventilator (SN-480-5; Shinano, Tokyo, Japan). The tidal vol-
ume and respiratory rate were set at 6 mL/kg and 40 strokes/min,
respectively. The right femoral artery was cannulated for mea-
surement of the blood pressure. The surface lead II electrocardio-
gram (ECG) was continuously monitored using a polygraph system
(RMP-6008; Nihon Kohden, Tokyo, Japan).
For production of complete atrioventricular block, a catheter
ablation technique was carried out according to our previous re-
ports (14,15). A quad-polar electrodes catheter with a tip of 1 mm
(6 Fr, D6DR252RT; Biosense Webster, Diamond Bar, CA, USA) was
inserted through the left femoral vein and positioned at the
tricuspid valve by watching the bipolar electrograms from the
distal electrodes pair. The optimal site for the atrioventricularnode ablation, namely, the compact atrioventricular node, was
determined on the basis of the intracardiac electrogram, of which
a very small His deﬂection was recorded. The power source for
atrioventricular node ablation was an electrosurgical generator
(SL-1PR; Semco, Tokyo, Japan) delivering continuous unmodu-
lated radiofrequency energy at a frequency of 500 kHz. After
proper positioning, the radiofrequency energy of 20 W was
delivered for 10 s from the tip electrode to the return electrode
positioned under the animal's back. The end point of this proce-
dure was the development of the complete atrioventricular block
with an onset of stable idioventricular escaped rhythm. The
ventricle was electrically driven with a stimulator (SEC-4103;
Nihon Kohden, Tokyo, Japan) at 60 beats/min throughout the
experiment. The stimulation pulses were rectangular in shape, of
2 V (approximately twice the threshold voltage) and 3 ms
duration.
A monophasic action potential (MAP) recording/pacing combi-
nation catheter (5 Fr, interectrode distance 1 mm; Physio-Tech,
Tokyo, Japan) was positioned at the right ventricle through the
right jugular vein. The signal was ampliﬁed with a differential
ampliﬁer (DAM 50,World Precision Instruments, Sarasota, FL, USA).
The duration of MAP signals was measured as an interval (ms) at
the 90% repolarization level, which was deﬁned as MAP90. Elec-
trophysiological and cardiovascular parameters were continuously
monitored with a polygraph system (RMP-6008; Nihon Kohden),
and analyzed with a fully automatic analysis system (ecgAUTO;
Emka Technologies, Paris, France).
2.2. Experimental protocol
Electrophysiological and cardiovascular parameters were
continuously recorded under the ventricular pacing at 60 beats/
min. After the basal control assessment (C), a low dose of
0.06 mg/kg of paliperidone was infused over 10 min via the left
femoral vein using an infusion pump (PHD 2000 Infusion; Instech
Laboratories, Plymouth Meeting, PA, USA), and changes in the
blood pressure, ECG and MAP90 were continuously monitored for
30 min. Next, a middle dose of 0.6 mg/kg was additionally
infused over 10 min, and each parameter was similarly moni-
tored. Finally, a high dose of 6 mg/kg was additionally infused
over 10 min, and changes in the blood pressure, ECG and MAP90
were monitored for 60 min. Also, the effects of risperidone in
doses of 0.03, 0.3 and 3 mg/kg were assessed in another series of
animals. Each data of the blood pressure, ECG and MAP90 was
obtained from the mean of three recordings, which was assessed
5, 10, 15, 20, 25 and 30 min after the low- and middle-dose
administration, and 5, 10, 15, 20, 25, 30, 40, 50 and 60 min af-
ter the high-dose administration. TdP was deﬁned as a poly-
morphic ventricular tachycardia, of which QRS complex twisted
around the baseline with 5 or more consecutive beats. Ventric-
ular tachycardia was deﬁned as more than lasting 5 consecutive
beats. Premature ventricular contraction with R on T phenome-
non was deﬁned by prematurity index (16), which was calculated
by dividing the coupling interval of the premature ventricular
contraction (RR0) by the QT interval of the preceding normally
conducted beat (¼RR0/QT). A premature ventricular contraction
with a prematurity index of <1 was considered to represent the R
on T phenomenon.
2.3. Beat-to-beat analysis
For assessment of instability of the ventricular repolarization,
the MAP90 of 31 consecutive beats was measured before and after
the drug administration (14,15). Poincare plots with MAP90(n)
versus MAP90(n þ 1) were prepared for each analysis time point.
Fig. 2. Typical tracings of electrocardiogram (ECG) showing torsades de pointes (TdP)
in the acute atrioventricular block rabbit. (A) Compressed tracing of the surface lead II
ECG after the high-dose administration of paliperidone (upper panel) or risperidone
(lower panel). Black inverted triangles represent onset of TdP. In the rabbit #5
receiving paliperidone at 6 mg/kg, 1 episode of short duration (<10 s) of TdP and 1
episode of longer duration (10 s) of the arrhythmia were observed. In the rabbit #1
receiving risperidone at 3 mg/kg, 5 episodes of short duration of TdP and 7 episodes of
longer duration of the arrhythmias were observed. (B) A magniﬁed ﬁgure of ECG,
monophasic action potential (MAP) and blood pressure (BP) signals. Paliperidone-
induced TdP was observed at 59 s in this rabbit.
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the Poincare plot was determined as short-term variability (¼Sj
MAP90(n þ 1)  MAP90(n) j/[30  √2]). On the other hand, the
mean distance to themean of the parameter parallel to the diagonal
of the Poincare plot was determined as long-term variability (¼Sj
MAP90(n þ 1) þ MAP90(n)  2MAP90(mean) j/[30  √2]).
2.4. Drug
Paliperidone (molecular weight ¼ 426.48) and risperidone
(molecular weight ¼ 410.48) were purchased from Tokyo Chemical
Industry (Tokyo, Japan). They were dissolved in 0.5% lactate solu-
tion and intravenously administered at an infusion rate of 0.2 mL/
kg per min. Heparin sodium, ketamine hydrochloride, xylazine
hydrochloride and isoﬂurane were purchased from AY Pharma-
ceuticals (Tokyo, Japan), Daiichi Sankyo (Tokyo, Japan), Bayer
Yakuhin (Tokyo, Japan) and Mylan Seiyaku (Osaka, Japan),
respectively.
2.5. Statistical analyses
Data are presented as the mean ± S.E.M. The statistical signiﬁ-
cances within a parameter were evaluated by one-way repeated-
measures analysis of variance (ANOVA) followed by Contrasts for
mean values comparison. A P-value less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Torsadogenic action of paliperidone and risperidone
Fig. 2A shows typical tracings of TdP arrhythmias in the acute
atrioventricular block rabbit after the high-dose administration of
paliperidone (upper panel) or risperidone (lower panel). The ar-
rhythmias followed a premature ventricular contraction that
occurred during the preceding T wave, known as R on T phenom-
enon, as shown in the magniﬁed ﬁgure (Fig. 2B).
The time courses of onset of arrhythmias after the administra-
tion of paliperidone and risperidone are summarized in Fig. 3A. In
the paliperidone group (n ¼ 6), premature ventricular contractions
with R on T phenomenonwere observed in 3 out of 6 animals at the
middle dose and all animals at the high dose. At the high dose,
episodes of TdP were detected in 2 out of 6 animals, and 1 animal
died after the latest TdP that degenerated into ventricular ﬁbrilla-
tion. In the risperidone group (n ¼ 6), premature ventricular con-
tractions with R on T phenomenon were observed in 2 out of 6
animals at the middle dose and all animals at the high dose. At the
high dose, episodes of TdP were detected in 4 out of 6 animals, and
2 animals died after the latest TdP that degenerated into ventricular
ﬁbrillation.
3.2. Effects of paliperidone and risperidone on the
electrophysiological and hemodynamic parameters
Fig. 3B shows the effects of paliperidone and risperidone on
the QT interval, MAP90 (upper panel), mean BP (middle panel) and
atrial rate (lower panel). The QT interval and MAP90 were pro-
longed by paliperidone as well as risperidone in a dose-
dependent manner. The extents of increase of the QT interval
and MAP90 by paliperidone were less than those in the risperi-
done group. Paliperidone slightly but signiﬁcantly decreased the
MBP and atrial rate, and similar results were obtained by risper-
idone except that the MBP transiently increased after the high-
dose administration.3.3. Beat-to-beat analysis for the temporal dispersion of
repolarization
Typical results of effects of paliperidone and risperidone on the
Poincare plots of the MAP90 are shown in Fig. 4. Table 1 summa-
rized the short-term and long-term variability of the MAP90 before
and after the drug administration. Paliperidone as well as risperi-
done at middle and high doses signiﬁcantly increased the short-
term variability of the MAP90, which were accompanied with sig-
niﬁcant prolongation of the MAP90.
4. Discussion
We assessed proarrhythmic effects of paliperidone using the
acute atrioventricular block rabbit (13), which were compared with
those of risperidone. The low dose of paliperidone did not affect
hemodynamic or electrophysiological parameters of the rabbit,
whereas the middle and high doses exerted proarrhythmic actions,
which was similar to those of risperidone as observed in this study.
Fig. 3. Proarrhythmic and electrophysiological effects of paliperidone (n ¼ 6) and risperidone (n ¼ 6) in the acute atrioventricular block rabbit. (A) Summary of proarrhythmic
effects of paliperidone (left panel) and risperidone (right panel). Each column indicates the responses of each rabbit to drugs. The columns are marked according to the
severity of arrhythmias developed in each minute. Black column means the occurrence of ventricular ﬁbrillation (VF), i.e., death. Red column means the occurrence of
ventricular tachycardia (VT) including torsades de pointes (TdP). Orange column means the occurrence of premature ventricular contraction (PVC) with the R on T phe-
nomenon. (B) Time course of the effects of paliperidone and risperidone on the QT interval, MAP duration at 90% repolarization level (MAP90), mean blood pressure (MBP) and
atrial rate. In the paliperidone group (left panels), the pre-drug control value (C) of QT interval, MAP90, MBP and atrial rate were 242 ± 13, 180 ± 12 ms, 38 ± 3 mmHg and
273 ± 6 beats/min, respectively, whereas those in the risperidone group (right panels) were 283 ± 12, 220 ± 13 ms, 40 ± 3 mmHg and 255 ± 10 beats/min, respectively. In the
experimental group receiving paliperidone, the MAP90 was prolonged in a dose-dependent manner, and obvious but statistically insigniﬁcant difference was detected in the
MAP90 10 min after the start of administration of 0.6 mg/kg (P ¼ 0.0522). The maximal changes in the MAP90 at 0.06, 0.6, and 6 mg/kg from pre-drug control value (C)
were þ5 ± 3, þ52 ± 10, and þ101 ± 30 ms respectively. The maximal changes in the experimental group receiving risperidone at 0.03, 0.3, and 3 mg/kg
were þ18 ± 7, þ105 ± 18, and þ147 ± 28 ms, respectively. Data are presented as mean ± S.E.M. The closed symbols represent the signiﬁcant differences from each pre-drug
control value (C) by P < 0.05.
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activating delayed rectiﬁer Kþ current (IKs) channels) and minK (b-
subunit for IKs channels) has been demonstrated to be lower than
that in human, resulting in small density of IKs, which is recognized
to provide the molecular basis for the sensitivity of the rabbit heart
to IKr blocker-induced repolarization abnormalities and related ar-
rhythmias (17).4.1. Experimental doses used in this study
Clinical application of risperidone has provided important
evidence that potent 5HT2A antagonism combined with milder
dopaminergic D2 antagonism resulted in signiﬁcantly improved
clinical signs and symptoms (18). In animal studies in vivo, sub-
cutaneous administration of paliperidone and risperidone
150
200
250
300
350
150 200 250 300 350
# 6 TdP(+)
0.6 mg/kg
STV: 5.3 ms
LTV: 3.4 ms
0.06 mg/kg
STV: 1.8 ms
LTV: 1.3 ms
6 mg/kg
STV: 7.0 ms
LTV: 12.9 ms
Control
STV: 1.6 ms
LTV: 1.6 ms
Paliperidone
150
200
250
300
350
150 200 250 300 350
Control
STV: 1.1 ms
LTV: 1.3 ms
0.03 mg/kg
STV: 1.4 ms
LTV: 1.4 ms
0.3 mg/kg
STV: 4.7 ms
LTV: 3.4 ms
3 mg/kg
STV: 5.8 ms
LTV: 4.6 ms
# 2 TdP(+)
Risperidone
M
AP
90
(n
+1
) (
m
s)
MAP90(n) (ms)
M
AP
90
(n
+1
) (
m
s)
MAP90(n) (ms)
Fig. 4. Typical examples of effects of paliperidone and risperidone on the Poincare plots of the duration of the monophasic action potential (MAP90) in the acute atrioventricular
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Table 1
Effects of paliperidone (n ¼ 6) and risperidone (n ¼ 6) on the beat-to-beat variability of the duration of the monophasic action potential (MAP90) in the acute atrioventricular
block rabbit.
Paliperidone (mg/kg) Risperidone (mg/kg)
Control 0.06 0.6 6 Control 0.03 0.3 3
STV (ms) 1.5 ± 0.2 1.8 ± 0.4 3.6 ± 0.5* 3.3 ± 1.0* 1.3 ± 0.1 2.3 ± 0.4 3.1 ± 0.5* 4.0 ± 0.8**
LTV (ms) 1.4 ± 0.3 1.5 ± 0.3 3.3 ± 0.5 4.4 ± 1.8* 1.4 ± 0.2 1.6 ± 0.1 3.0 ± 0.4 8.1 ± 2.1***
MAP90 (ms) 182 ± 12 186 ± 11 235 ± 23* 261 ± 39*** 221 ± 13 233 ± 14 325 ± 25*** 351 ± 34***
STV: short-term variability, LTV: long-term variability. Data are presented as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 compared with corresponding pre-drug control.
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and 0.056 mg/kg, respectively (19), showing that 5HT2A antago-
nism by paliperidone is estimated to be roughly half as potent as
that by risperidone. On the other hand, intravenously adminis-
tered 0.03 mg/kg of risperidone over 10 min is estimated to be
clinically relevant based on our previous study using halothane-
anesthetized animals (12). Thus, the present study for paliper-
idone can be considered to be carried out under the therapeutic
(0.06 mg/kg, i.v.) to supra-therapeutic (0.6e6 mg/kg, i.v.) levels.
Although plasma concentrations of testing drugs were not
measured in this study, we have already conﬁrmed that the
plasma concentration of a clinically relevant dose of risperidone
(0.03 mg/kg, i.v.) was 0.125 mM in dogs, whereas those of supra-
therapeutic doses (0.3 and 3 mg/kg, i.v.) were 1.176 and
8.223 mM, respectively (12).4.2. Torsadogenic action of paliperidone
As shown in Figs. 2 and 3, paliperidone increased the number of
premature ventricular contractions with R on T phenomenon at the
middle dose and induced TdP at the high dose, which were not
observed at the low dose. Premature ventricular contractions with
R on T phenomenon, associated with early afterdepolarization
(EAD)-induced triggered activity, have been known to be able to
initiate the development of TdP when transmural dispersion of
repolarization is exaggerated (20). The proarrhythmic mechanisms
may be associated with electrophysiological effects of paliperidone,
showing suppression of hERG Kþ channels with IC50 values of
0.528e1.3 mM (9,21e23), slight inhibition of Naþ channels by 15%
and L-type Ca2þ channels by 14% at 10 mM, and no effects on the IKsat 10 mM (22). In our previous study using the same animal model,
TdP arrhythmias can be ﬁnely detected after the administration of a
class III antiarrhythmic drug nifekalant at 3 mg/kg (10 times higher
dose for clinical use) (13), whose sensitivity was similar to that of a
well-established in vivo canine TdP model (24). Also, the middle
and high doses of paliperidone signiﬁcantly increased the short-
term variability of the ventricular repolarization period, which is
a well-established predictive marker of proarrhythmia, reﬂecting
the premonitory phenomenon of EAD (25). These results suggest
that paliperidone has torsadogenic potential at supra-therapeutic
doses, which may partly explain the results of the Early Post-
marketing Phase Vigilance for the prolonged release suspension
of paliperidone palmitate showing 12 cases of sudden death and 4
cases of suspected sudden death in the 32 fatal cases (7). More
importantly, paliperidone was prescribed in combination with
other antipsychotics in 25 out of 32 fatal cases. Thus, more careful
plan for drug administration might have been required for these
patients.4.3. Comparison with torsadogenic potential of risperidone
Paliperidone has been reported to suppress hERG Kþ channels
expressed in HEK293 cells with IC50 values of 0.528e1.3 mM
(9,21e23). Since the IC50 values of risperidone have been shown to
be 0.148e0.65 mM (21,23,26), effects of paliperidone on the hERG
Kþ channels are estimated to be roughly half as potent as those of
risperidone. As shown in Figs. 2 and 3, risperidone increased the
number of premature ventricular contractions with R on T phe-
nomenon at the middle dose and induced TdP at the high dose.
Similarly, it has been reported that supra-therapeutic dose of
M. Hagiwara et al. / Journal of Pharmacological Sciences 132 (2016) 48e54 53risperidone (3 mg/kg) signiﬁcantly increased the electrically
vulnerability period of the ventricular muscle in the halothane-
anesthetized canine model (12). Meanwhile, clinically relevant
dose of 0.06 mg/kg of paliperidone or 0.03 mg/kg of risperidone
hardly affected the ECG parameters in this study. These in vivo
observations are essentially in accordance with a systematic review
of case reports, where risperidone is suggested to be a relatively
safe drug in the context of QT interval prolongation and TdP when
properly prescribed (27). Since torsadogenic potential of paliper-
idone can be estimated to be equal or slightly subordinate in
comparison with that of risperidone based on the current study,
caution has to be paid for patients with TdP risks on the prescrip-
tion of paliperidone as well as risperidone (27).
4.4. Clinical implications
This study provides information for the torsadogenic potential
of paliperidone using the acute atrioventricular block rabbit, which
is adopted as a proarrhythmia model (13). Since contribution of IKs
channels to repolarization phase in the rabbit ventricular myocytes
has been demonstrated to be lower than that in the healthy human
(17), the current results may correspond to effects of paliperidone
in patients with congenital long QT syndrome type 1 or heart dis-
eases complicating secondarily down-regulated IKs, such as sus-
tained bradycardia (28,29). More importantly, cardiovascular
morbidity and mortality are important problems in patients with
schizophrenia, because a wide spectrum of reasons, ranging from
genes to the environment, are held responsible for causing the
cardiovascular risk factors that can lead to shortening the life ex-
pectancy of patients with schizophrenia (30). Furthermore,
concomitant use of antipsychotics or other drugs with the pro-
pensity of prolongation of the QT interval may lead to marked QT
prolongation (31,32). Although paliperidone has been reported to
cause a modest increase in the QT interval in clinical practice (3,8),
we have to recognize that the drug has an inherent proarrhythmic
action.
4.5. Conclusions
Paliperidone showed torsadogenic potential at supra-
therapeutic doses in this study, whose potency can be estimated
to be equal or slightly subordinate in comparison with that of ris-
peridone. Caution has to be paid for patients with TdP risks on the
prescription of paliperidone as well as risperidone since the drug
has an inherent proarrhythmic action.
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